Astrophysics Strategic Mission Concept Studies

Novaremed’s Non-opioid Lead Compound, NRD.E1, to be Tested in NIH HEAL Initiative Phase 2 Trial for the Treatment of Chronic Pain

Retrieved on: 
Tuesday, December 21, 2021
Oncology, Health, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Doctor of Philosophy, Adult, Review, Neuropathic pain, Chronic pain, Astrophysics Strategic Mission Concept Studies, PDPN, Board, European Journal of Pain, National, Diabetes, European Journal, Sleep, IND, CIPN, Chemotherapy-induced peripheral neuropathy, Safety, Prevalence, MD, Fast track (FDA), Pharmacokinetics, Nerve injury, NIH, Cancer, Patient, US, Pharmaceutical industry, Dentistry, Pain, NRD.E1, NIH, NIH-HEAL and EPPIC-Net, peripheral neuropathy and associated neuropathic pain, Novaremed, NRD.E1, NIH, NIH-HEAL AND EPPIC-NET, PERIPHERAL NEUROPATHY AND ASSOCIATED NEUROPATHIC PAIN, NOVAREMED

After a thorough review by pain experts, Novaremed has received NIH confirmation for funding and execution of a Phase 2b study with NRD.E1 in patients with PDPN.

Key Points: 
  • After a thorough review by pain experts, Novaremed has received NIH confirmation for funding and execution of a Phase 2b study with NRD.E1 in patients with PDPN.
  • For this phase 2 investigational trial, Novaremed will provide drug supply and EPPIC-Net (Early Phase Pain Investigation Clinical Network), which is part of the NIH HEAL Initiative, will run the study in the United States.
  • The EPPIC-Net (Early Phase Pain Investigation Clinical Network) is part of the NIH HEAL Initiative and seeks to enhance the treatment of acute and chronic pain and reduce reliance on opioids by accelerating early-phase clinical trials of non-addictive treatments for pain.
  • Many of the currently available products for the treatment of chronic neuropathic pain have limited efficacy and are often not well tolerated.

HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021

Retrieved on: 
Thursday, October 28, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fibrosis, Program, UDCA, Astrophysics Strategic Mission Concept Studies, Orphan drug, Weight loss, Central nervous system disease, 2021 Essex County Council election, AASLD, Primary sclerosing cholangitis, Fatty liver disease, Ursodeoxycholic acid, PBC, US, Association, CNS, NAFLD, Fast Track, T2DM, Patient, Liver injury, Roy Taylor (scientist), ALT, Cholestasis, Liver disease, American Association for the Study of Liver Diseases, HighTide, Chronic liver disease, PSC, American Association, Therapy, NASH, Diabetes, Doctor of Philosophy, Berberine, Primary biliary cholangitis, Pharmaceutical industry, Medical imaging, Dietary supplement, HTD1801, HighTide Therapeutics, HTD1801, HIGHTIDE THERAPEUTICS

HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).
  • The data will be presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2021, being held virtually November 12-15, 2021.
  • We are excited to present new HTD1801 clinical data in both PSC and NASH, said Liping Liu, PhD, Founder and Chief Executive Officer of HighTide.
  • HTD1801 has received Fast Track designation from the US FDA for both PSC and NASH, as well as Orphan Drug designation for PSC.

Greenland Resources Appoints Jens Moberg as Senior Advisor

Retrieved on: 
Tuesday, October 19, 2021
Tetra, Tetra Tech, Family, Frankfurt Stock Exchange, Mining, Social impact assessment, IEA, Corporation, Partner, Association, Senior advisor, Ontario Securities Commission, PostNord, Feasibility study, European Union, Astrophysics Strategic Mission Concept Studies, Senior, DRA, Biography, Hardenability, Molybdenum disulfide, Board, Sustainability metrics and indices, World Bank, GLOBE, European Advisory Commission, NEO, SRK, Industry, Engineering, Copenhagen Business School, Union, National instrument, LEGO, Molybdenum, Environment, Marketing, Biophysical environment, Company, Steel, Rare-earth element, Security (finance)

To this extent, Mr. Jens Moberg will join as Senior Advisor.

Key Points: 
  • To this extent, Mr. Jens Moberg will join as Senior Advisor.
  • Jens has had a 14 year long and very successful career in Microsoft, including leading sales, marketing and services in North America.
  • Jens is engaged in volunteer work including the role as ambassador for The Danish Cancer Society and for The Danish Heart Foundation.
  • Mr. Jens Moberg commented: I am very excited about joining Greenland Ressources as a Senior Advisor.

Greenland Resources Announces Updated Mineral Resource Estimate on Its Malmbjerg Molydenum Project

Retrieved on: 
Tuesday, October 12, 2021
Tetra, Company, National instrument, Mining, Resource, Classification, Tetra Tech, Orientation, Astrophysics Strategic Mission Concept Studies, Engineering, Biophysical environment, Social impact assessment, Technical report, Industry, Arcturus, SEDAR, Molybdenum, Wireframe, NI 43-101, SRK, Ontario Securities Commission, Resource management, MMTS, Sustainability metrics and indices, Molybdenum disulfide, National Instrument 43-101, Feasibility study, DRA, Uranium, Rare-earth element

The Malmbjerg Molybdenum Deposit Mineral Resource Estimate has been estimated in accordance with the 2014 CIM Definition Standards and using the 2019 CIM Best Practices Guidelines.

Key Points: 
  • The Malmbjerg Molybdenum Deposit Mineral Resource Estimate has been estimated in accordance with the 2014 CIM Definition Standards and using the 2019 CIM Best Practices Guidelines.
  • Tetra Tech has reviewed the resource estimate done by Moose Mountain Technical Services (MMTS).
  • The underground channel samples used for the resource estimate were confirmed to be consistent with sampling appropriate for resource estimation along the entire length of the adits.
  • Mineral Resources for the Malmbjerg Molybdenum Project have been estimated by Sue Bird, P.Eng of MMTS, an "independent qualified person" as such term is defined in NI 43-101.